This funding opportunity supports rigorous preclinical validation of drug targets and early-stage drug discovery for Alzheimer's disease and related dementias. It focuses on novel candidate targets and therapeutic modalities including small molecules and biologics. Applications will utilize the U01 activity code and clinical trials are not allowed. Investigators are encouraged to develop collaborations and responsive projects in this research area.
Eligible applicants include a wide range of organizations such as government entities, educational institutions, tribal governments and organizations, nonprofits, for-profit organizations including small businesses, and foreign institutions. Specific eligibility details are provided in the full anno
